

OMB APPROVAL	
OMB Number:	3235-0287
Estimated average burden	
hours per response:	0.5

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person* <u>Antibody Investments LLC</u> <hr/> (Last) (First) (Middle) 7 HARTOM STREET, 2ND FLOOR, HAR HOTZVIM <hr/> (Street) JERUSALEM L3 9777507 <hr/> (City) (State) (Zip)			2. Issuer Name and Ticker or Trading Symbol <u>VACCINEX, INC. [VCNX]</u>			5. Relationship of Reporting Person(s) to Issuer (Check all applicable) Director <input checked="" type="checkbox"/> 10% Owner Officer (give title below) Other (specify below)		
			3. Date of Earliest Transaction (Month/Day/Year) 08/13/2018					
			4. If Amendment, Date of Original Filed (Month/Day/Year)					
			6. Individual or Joint/Group Filing (Check Applicable Line) <input checked="" type="checkbox"/> Form filed by One Reporting Person <input type="checkbox"/> Form filed by More than One Reporting Person					

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned

1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price			
Common Stock	08/13/2018		C		1,346,139	A	(1)	1,346,139	D	
Common Stock	08/13/2018		C		549,444	A	(2)	1,895,583	D	

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares				
Series C Convertible Preferred Stock	(1)	08/13/2018		C			7,205,882	(1)	(1)	Common Stock	1,346,139	(1)	0	D	
Series D Convertible Preferred Stock	(2)	08/13/2018		C			5,494,505	(2)	(2)	Common Stock	549,444	(2)	0	D	

1. Name and Address of Reporting Person* <u>Antibody Investments LLC</u> <hr/> (Last) (First) (Middle) 7 HARTOM STREET, 2ND FLOOR, HAR HOTZVIM <hr/> (Street) JERUSALEM L3 9777507 <hr/> (City) (State) (Zip)		
1. Name and Address of Reporting Person* <u>Shumacher Michael</u> <hr/> (Last) (First) (Middle) 7 HARTOM STREET, 2ND FLOOR, HAR HOTZVIM <hr/> (Street) JERUSALEM L3 9777507 <hr/> (City) (State) (Zip)		

Explanation of Responses:

- The reported securities converted into shares of Common Stock on a 0.1868-for-1 basis immediately prior to the consummation of the Issuer's initial public offering.
- The reported securities converted into shares of Common Stock on a 1-for-10 basis immediately prior to the consummation of the Issuer's initial public offering.

Remarks:

Michael Shumacher is the sole manager of Antibody Investments LLC. Mr. Shumacher disclaims beneficial ownership of the reported securities except to the extent of his pecuniary interest therein.

ANTIBODY INVESTMENTS 08/15/2018
LLC By: /s/ Michael Shumacher,

Manager

/s/ Michael Shumacher

08/15/2018

** Signature of Reporting Person

Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.